Compare · ARGX vs INTS
ARGX vs INTS
Side-by-side comparison of argenx SE (ARGX) and Intensity Therapeutics Inc. (INTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and INTS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 4160.0x INTS ($12.8M).
- Over the past year, ARGX is up 52.5% and INTS is down 41.3% - ARGX leads by 93.8 points.
- INTS has been more active in the news (5 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 0 for INTS).
- Company
- argenx SE
- Intensity Therapeutics Inc.
- Price
- $861.30+0.30%
- $4.74-3.46%
- Market cap
- $53.41B
- $12.8M
- 1M return
- -1.91%
- +26.06%
- 1Y return
- +52.49%
- -41.34%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2023
- News (4w)
- 3
- 5
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest INTS
- Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
- SEC Form S-8 filed by Intensity Therapeutics Inc.
- Principal Accounting Officer Wesolowski John M was granted 3,688 shares, increasing direct ownership by 108% to 7,102 units (SEC Form 4)
- Chief Financial Officer Talamo Joseph was granted 1,093 shares, increasing direct ownership by 95% to 2,239 units (SEC Form 4)
- Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
- Intensity Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
- Intensity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Intensity Therapeutics Inc.